Phase 3 randomised controlled trial (CheckMate -274) of adjuvant treatment with nivolumab in muscle-invasive urothelial cancer meets primary endpoint

Adjuvant nivolumab improved disease-free survival (DFS) in patients with surgically resected, high-risk muscle-invasive urothelial cancer. Median DFS survival: 21.0 mths vs 10.9 mths with placebo, a risk reduction of 30% (HR 0.70, 98.31% CI: 0.54 – 0.89, p<0.001).

Source:

Biospace Inc.